Cargando…

Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen

OBJECTIVES: We investigated whether companion drug resistance was associated with adverse outcomes of the shorter multidrug-resistant tuberculosis (MDR-TB) treatment regimen in Bangladesh after adjustment for fluoroquinolone resistance. METHODS: MDR-TB/rifampicin-resistant tuberculosis patients regi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lempens, Pauline, Decroo, Tom, Aung, Kya J.M., Hossain, Mohammad A., Rigouts, Leen, Meehan, Conor J., Van Deun, Armand, de Jong, Bouke C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670168/ https://www.ncbi.nlm.nih.gov/pubmed/32829049 http://dx.doi.org/10.1016/j.ijid.2020.08.042

Ejemplares similares

Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh
por: Lempens, Pauline, et al.
Publicado: (2023)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations
por: Lempens, Pauline, et al.
Publicado: (2018)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
por: Van Deun, Armand, et al.
Publicado: (2022)

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations
por: Ng, Kamela C. S., et al.
Publicado: (2018)

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
por: Ngabonziza, Jean Claude Semuto, et al.
Publicado: (2020)

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021)

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
por: Villellas, Cristina, et al.
Publicado: (2017)

GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
por: Rigouts, Leen, et al.
Publicado: (2023)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases
por: Ngabonziza, Jean Claude S, et al.
Publicado: (2021)

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence
por: Trébucq, Arnaud, et al.
Publicado: (2019)

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis
por: Coeck, Nele, et al.
Publicado: (2016)

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results
por: Ng, Kamela Charmaine, et al.
Publicado: (2018)

Bridging the TB data gap: in silico extraction of rifampicin-resistant tuberculosis diagnostic test results from whole genome sequence data
por: Ng, Kamela C. S., et al.
Publicado: (2019)

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
por: Mallick, Jahan Saeed, et al.
Publicado: (2022)

False Rifampicin Resistance in Xpert Ultra Applied to Lymph Node Aspirate: A Case Report
por: Ng, Kamela C S, et al.
Publicado: (2020)

Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century
por: Ngabonziza, Jean Claude S., et al.
Publicado: (2022)

GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions
por: Farhat, Maha R., et al.
Publicado: (2019)

Storage of Sputum in Cetylpyridinium Chloride, OMNIgene.SPUTUM, and Ethanol Is Compatible with Molecular Tuberculosis Diagnostic Testing
por: Sanoussi, C. N’Dira, et al.
Publicado: (2019)

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance
por: Torrea, Gabriela, et al.
Publicado: (2019)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Drug-resistant tuberculosis: Progress towards shorter and safer regimens
por: Saravu, Kavitha, et al.
Publicado: (2019)

Towards all-oral and shorter treatment regimens for drug-resistant tuberculosis
por: Weyer, Karin, et al.
Publicado: (2018)

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan
por: du Cros, Philipp, et al.
Publicado: (2021)

Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis
por: Patankar, Sayalee, et al.
Publicado: (2023)

Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2023)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal
por: Koirala, S., et al.
Publicado: (2021)

Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
por: Souleymane, Mahamadou Bassirou, et al.
Publicado: (2022)

Reconstituting the genus Mycobacterium
por: Meehan, Conor J., et al.
Publicado: (2021)

Targeted next-generation sequencing of sputum for diagnosis of drug-resistant TB: results of a national survey in Democratic Republic of the Congo
por: Kayomo, Michel Kaswa, et al.
Publicado: (2020)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Prior exposure to Bordetella species as an exclusion criterion in the baboon model of pertussis
por: NGUYEN, Annalee W., et al.
Publicado: (2016)

Should Subclinical Hypothyroidism Be an Exclusion Criterion for the Diagnosis of Polycystic Ovary Syndrome?
por: de-Medeiros, Sebastião Freitas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jlpdui0kdq8vf7mldtipu17eas